Journal article
Evaluation of reduced susceptibility to quaternary ammonium compounds and bisbiguanides in clinical isolates and laboratory-generated mutants of Staphylococcus aureus
Antimicrobial Agents and Chemotherapy, Vol.57(8), pp.3488-3497
2013
Abstract
The MICs and minimum bactericidal concentrations (MBCs) for the biocides benzalkonium chloride and chlorhexidine were determined against 1,602 clinical isolates of Staphylococcus aureus. Both compounds showed unimodal MIC and MBC distributions (2 and 4 or 8 mg/liter, respectively) with no apparent subpopulation with reduced susceptibility. To investigate further, all isolates were screened for qac genes, and 39 of these also had the promoter region of the NorA multidrug-resistant (MDR) efflux pump sequenced. The presence of qacA, qacB, qacC, and qacG genes increased the mode MIC, but not MBC, to benzalkonium chloride, while only qacA and qacB increased the chlorhexidine mode MIC. Isolates with a wild-type norA promoter or mutations in the norA promoter had similar biocide MIC distributions; notably, not all clinical isolates with norA mutations were resistant to fluoroquinolones. In vitro efflux mutants could be readily selected with ethidium bromide and acriflavine. Multiple passages were necessary to select mutants with biocides, but these mutants showed phenotypes comparable to those of mutants selected by dyes. All mutants showed changes in the promoter region of norA, but these were distinct from this region of the clinical isolates. Still, none of the in vitro mutants displayed fitness defects in a killing assay in Galleria mellonella larvae. In conclusion, our data provide an in-depth comparative overview on efflux in S. aureus mutants and clinical isolates, showing also that plasmid-encoded efflux pumps did not affect bactericidal activity of biocides. In addition, current in vitro tests appear not to be suitable for predicting levels of resistance that are clinically relevant.
Details
- Title
- Evaluation of reduced susceptibility to quaternary ammonium compounds and bisbiguanides in clinical isolates and laboratory-generated mutants of Staphylococcus aureus
- Authors/Creators
- L. Furi (Author/Creator)M.L. Ciusa (Author/Creator)D. Knight (Author/Creator)V. Di Lorenzo (Author/Creator)N. Tocci (Author/Creator)D. Cirasola (Author/Creator)L. Aragones (Author/Creator)J.R. Coelho (Author/Creator)A.T. Freitas (Author/Creator)E. Marchi (Author/Creator)L. Moce (Author/Creator)P. Visa (Author/Creator)J.B. Northwood (Author/Creator)C. Viti (Author/Creator)E. Borghi (Author/Creator)G. Orefici (Author/Creator)I. Morrissey (Author/Creator)M.R. Oggioni (Author/Creator)
- Publication Details
- Antimicrobial Agents and Chemotherapy, Vol.57(8), pp.3488-3497
- Publisher
- American Society for Microbiology
- Identifiers
- 991005540375007891
- Copyright
- © 2013, American Society for Microbiology
- Murdoch Affiliation
- Murdoch University
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
26 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.23 Antibiotics & Antimicrobials
- 1.23.173 MRSA and VRE
- Web Of Science research areas
- Microbiology
- Pharmacology & Pharmacy
- ESI research areas
- Pharmacology & Toxicology